Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Ann Allergy Asthma Immunol. 2014 Sep;113(3):295-300. doi: 10.1016/j.anai.2014.05.026. Epub 2014 Jun 24.
Bronchial asthma is a chronic inflammatory disorder characterized by airway hyperresponsiveness and airflow limitation. Connective tissue growth factor (CTGF), one of the key profibrotic factors associated with transforming growth factor β, may be related to airway remodeling in asthma. However, no data are available on the association between plasma CTGF levels and clinical and physiologic parameters in patients with asthma. Recently, we developed a novel subtraction method for determination of plasma CTGF levels.
To investigate the utility of plasma CTGF level as a surrogate biomarker in asthma.
Plasma CTGF levels were measured in 67 patients with stable asthma and 81 healthy volunteers, using the subtraction method. We evaluated correlations between plasma CTGF levels and clinical and physiologic parameters in patients with asthma.
Plasma CTGF levels were higher in patients with asthma than in healthy volunteers. Asthmatic patients with a percentage of predicted forced expiratory volume in 1 second (FEV1) less than 80% had significantly higher levels of plasma CTGF than those with a percentage of predicted FEV1 of 80% or more. In patients with asthma, plasma CTGF levels had significantly negative correlations with forced vital capacity (FVC), FEV1, percentage of predicted FEV1, FEV1/FVC ratio, forced expiratory flow at 50% of the FVC (FEF50%), percentage of predicted FEF50%, forced expiratory flow at 75% of the FVC (FEF75%), and percentage of predicted FEF75%, parameters that reflect the degree of airway obstruction. Plasma CTGF levels were negatively correlated with Asthma Control Test scores, a patient-based index of clinical control of asthma.
Plasma CTGF may be a potential biomarker for stable asthma when evaluating the degree of persistent airway obstruction.
umin.ac.jp/ctr Identifier: UMIN000013081.
支气管哮喘是一种慢性炎症性疾病，其特征为气道高反应性和气流受限。结缔组织生长因子（CTGF）是与转化生长因子β相关的关键致纤维化因子之一，可能与哮喘中的气道重塑有关。然而，目前尚无关于哮喘患者血浆 CTGF 水平与临床和生理参数之间关系的资料。最近，我们开发了一种用于测定血浆 CTGF 水平的新的减法方法。
探讨血浆 CTGF 水平作为哮喘替代生物标志物的作用。
采用减法法测量 67 例稳定期哮喘患者和 81 例健康志愿者的血浆 CTGF 水平。我们评估了哮喘患者血浆 CTGF 水平与临床和生理参数之间的相关性。
哮喘患者的血浆 CTGF 水平高于健康志愿者。第 1 秒用力呼气量占预计值的百分比（FEV1）＜80%的哮喘患者的血浆 CTGF 水平显著高于 FEV1 占预计值 80%或以上的患者。在哮喘患者中，血浆 CTGF 水平与用力肺活量（FVC）、FEV1、FEV1 占预计值的百分比、FEV1/FVC 比值、FVC 时 50%的用力呼气流量（FEF50%）、FEF50%占预计值的百分比、FVC 时 75%的用力呼气流量（FEF75%）和 FEF75%占预计值的百分比呈显著负相关，这些参数反映了气道阻塞的程度。血浆 CTGF 水平与哮喘控制测试评分（一种基于患者的哮喘临床控制指数）呈负相关。
在评估持续性气道阻塞程度时，血浆 CTGF 可能是稳定型哮喘的潜在生物标志物。
umin.ac.jp/ctr 标识符：UMIN000013081。
